N6-methyladenosine modification promotes hepatocarcinogenesis through circ-CDYL-enriched and EpCAM-positive liver tumor-initiating exosomes
Quick Facts
- Publication title: N6-methyladenosine modification promotes hepatocarcinogenesis through circ-CDYL-enriched and EpCAM-positive liver tumor-initiating exosomes
- Journal: iScience
- Year: 2023
- DOI: 10.1016/j.isci.2023.108022
- PMID/PMCID: 37954137; PMC10638478
Research overview
We found that Circ-CDYL is highly enriched in early HCC plasma exosomes. We found that Circ-CDYL is highly enriched in early HCC plasma exosomes.
Key findings
CircRNAs play multiple roles in a variety of cellular processes.
We found that Circ-CDYL is highly enriched in early HCC plasma exosomes.
Moreover, EpCAM+ HCC cells and exosomes had significant Circ-CDYL levels.
We postulated that Circ-CDYL-enriched and EpCAM-positive exosomes would function as liver tumor-initiating exosomes (LTi-Exos).
Echo Biotech Role
Echo Biotech contributed EV characterization.
Related platforms: Exoomics®
Related services and capabilities: EV Basic Characterization (TEM/NTA/WB)
References
Original publication: N6-methyladenosine modification promotes hepatocarcinogenesis through circ-CDYL-enriched and EpCAM-positive liver tumor-initiating exosomes iScience. 2023. DOI: 10.1016/j.isci.2023.108022. PMID/PMCID: 37954137; PMC10638478.